-+ 0.00%
-+ 0.00%
-+ 0.00%

Atossa Therapeutics shareholders approve reverse stock split authorization

PUBT·05/08/2026 12:02:59
Listen to the news
Atossa Therapeutics shareholders approve reverse stock split authorization
  • Atossa Therapeutics held its annual stockholder meeting on May 7, 2026.
  • Stockholders backed an amendment to certificate of incorporation authorizing board to implement a reverse stock split, if it determines one is necessary or appropriate, at a ratio ranging from 2-for-1 to 20-for-1.
  • Ernst & Young was ratified as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-213373), on May 08, 2026, and is solely responsible for the information contained therein.